The United States is responsible for around eighty percent of the world's total consumption of opioids, as stated by the American Society of Interventional Pain Physicians. It was reported in May 2015 by the American Gastroenterological Association that chronic constipation affects one in six people in the United States and is the third-leading symptom that prompts outpatient clinic visits in the country. The article was published in the American Gastroenterological Association. Overweight women are disproportionately affected by this condition. Europe has a high acuity information system, a high degree of disposable wealth, and widespread acceptance of unhealthy lifestyle choices, all of which combine to make it a potential high growth market. The Asia-Pacific region is also anticipated to be a lucrative market for the treatment of constipation. This is mostly owing to the region's expanding westernization, which is defined by the region's rising acceptance of non-nutritious fast food.
The major players operating in Constipation Treatment Market include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., C.B. Fleet Company Inc., Daewoong Co. Ltd., Sucampo Pharmaceuticals Inc., Cosmo Pharmaceuticals, Synergy Pharmaceuticals Inc. Boehringer Ingelheim GmbH, and Ironwood Pharmaceuticals.
Key Competitors in the Constipation Treatment Industry:
1. Astrazeneca plc
Astrazeneca plc was founded in 1999 and its headquarter Cambridge, United Kingdom. The company operates in 15 countries.
2.takeda Pharmaceutical Company Limited,,
takeda Pharmaceutical Company Limited, founded in 1781, and it’s located in Doshomachi, Osaka, Japan The company operates in 80 Countries. In2018 Takeda Pharmaceutical Company Limited today announced options for the treatment of chronic idiopathic constipation